1242881-37-3

Basic information

• Product Name: (R)-2-Mercaptobutanoic acid
• Synonyms: (R)-2-Mercaptobutanoic acid
• CAS NO: 1242881-37-3
• Molecular Formula: C4H8O2S
• Molecular Weight: 120.17012
• Mol File: 1242881-37-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-2-Mercaptobutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-Mercaptobutanoic acid(1242881-37-3)
• EPA Substance Registry System: (R)-2-Mercaptobutanoic acid(1242881-37-3)

Safety Data

• Hazardous Substances Data: 1242881-37-3(Hazardous Substances Data)

Usage

General Description

(R)-2-Mercaptobutanoic acid, also known as R-2-Methyl-3-mercaptopropionic acid, is a chemical compound with the molecular formula C4H8O2S. It is a chiral molecule, meaning it has a non-superimposable mirror image, and is classified as a thiol compound due to its containing a sulfur atom bonded to a hydrogen atom. It is commonly used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. In addition, it is also used in the manufacturing of chemical and polymer materials. Its unique properties and structural features make it a valuable building block in organic synthesis and drug development.

Upstream product

• 2681-94-9 (2R)-2-bromobutanoic acid 

Relevant articles and documents

Rational design of partial agonists for the muscarinic M1 acetylcholine receptor

Aiming to design partial agonists for a G-protein-coupled receptor based on dynamic ligand binding, we synthesized three different series of bipharmacophoric ligands composed of the orthosteric building blocks iperoxo and 1 linked to allosteric modulators (BQCA-derived compounds, BQCAd; TBPB-derived compound, TBPBd). Their interactions were studied with the human muscarinic acetylcholine M1-receptor (hM1) with respect to receptor binding and Gq-protein signaling. Results demonstrate that iperoxo/BQCAd (2, 3) and 1/BQCAd hybrids (4) act as M1 partial agonists, whereas 1/TBPBd hybrids (5) did not activate M1-receptors. Among the iperoxo/BQCAd-hybrids, spacer length in conjunction with the pattern of substitution tuned efficacy. Most interestingly, a model of dynamic ligand binding revealed that the spacer length of 2a and 3a controlled the probability of switch between the inactive purely allosteric and the active bitopic orthosteric/allosteric binding pose. In summary, dynamic ligand binding can be exploited in M1 receptors to design partial agonists with graded efficacy.